Journal Article (Review Article)

DKFZ-2024-01618

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Refining the role of N6-methyladenosine in cancer.

Koch, J. (First author)DKFZ* ; Lyko, F. (Last author)DKFZ*

2024
Elsevier Amsterdam

This record in other databases:

Please use a persistent id in citations: doi:10.1016/j.gde.2024.102242

Abstract: N6-methyladenosine (m6A) is the most abundant internal modification of eukaryotic mRNAs. m6A affects the fate of its targets in all aspects of the mRNA life cycle and has important roles in various physiological and pathophysiological processes. Aberrant m6A patterns have been observed in numerous cancers and appear closely linked to oncogenic phenotypes. However, most studies relied on antibody-dependent modification detection, which is known to suffer from important limitations. Novel, antibody-independent, quantitative approaches will be critical to investigate changes in the m6A landscape of cancers. Furthermore, pharmaceutical targeting of the m6A writer Methyltransferase-like 3 (METTL3) has demonstrated the potential to modulate cancer cell phenotypes. However, the enzyme also appears to be essential for the viability of healthy cells. Further refinement of therapeutic strategies is therefore needed to fully realize the potential of m6A-related cancer therapies.

Note: #EA:A130#LA:A130# / DKFZ-ZMBH Alliance

---

Contributing Institute(s):

1. A130 Epigenetik (A130)

Research Program(s):

1. 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)

Appears in the scientific report 2024

---

Database coverage:
; BIOSIS Previews ; BIOSIS Reviews Reports And Meetings ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection ; Zoological Record

---